From November 15 to 17, 2024, the Chinese Congress on Holistic Integrative Oncology (CCHIO)(CCHIO) was held in Xi’an under the theme "Winning in Integration: Tumor Prevention and Treatment." In the breast cancer domain, the conference integrated the latest global advancements in diagnosis, treatment, and research. At the event, Oncology Frontier interviewed Dr. Jin Zhang, Chair of The Chinese Anti-Cancer Association, Committee of Breast Cancer Society (CACA-CBCS) and a renowned expert from Tianjin Medical University Cancer Institute and Hospital. Professor Zhang shared her insights into the development of breast oncology in China, focusing on HR-positive breast cancer, and discussed the current landscape and future of precision diagnosis and treatment in this area.

With advancements in breast cancer diagnosis and treatment, alongside the increasing diversity of patient needs, a comprehensive evaluation of treatment outcomes and improved quality of life have become focal points in this field. In recent years, Patient-Reported Outcomes (PROs) have emerged as a novel evaluation tool, playing an increasingly important role in breast cancer care. PROs go beyond traditional objective assessments like imaging and lab tests by emphasizing patients' subjective experiences, offering a new lens for both clinicians and patients to evaluate treatment effectiveness and quality of life. At the 2024 Breast Cancer Standardized Diagnosis and Quality Control Conference, Oncology Frontier interviewed Dr. Quchang Ouyang from Hunan Cancer Hospital to discuss the current applications, future trends, and significance of PROs in enhancing breast cancer diagnosis and treatment.

At the recent The 9th Congress of the Chinese Chapter of the International Hepato-Pancreato-Biliary Association (CCIHPBA), Prof. Chaoliu Dai from Shengjing Hospital of China Medical University presented on “Controlling Intraoperative Hemorrhage and Protecting Residual Liver Function in Hepatectomy.” Oncology frontier invited Prof. Dai to delve further into this topic and share insights from his presentation.

The clinical use of immune checkpoint inhibitors (ICIs) offers a promising approach for locally advanced gastric and gastroesophageal junction (GEJ) cancers, potentially improving cure rates. Recent clinical trials have demonstrated that ICIs combined with chemotherapy, chemoradiotherapy, anti-HER2, or anti-VEGF agents exhibit synergistic and complementary effects. Compared to chemotherapy alone, these combinations show improved pathologic complete response (pCR) rates, major response rates, ypT0N0 rates, and potentially improve patient outcomes. At the recent 2024 CACA Integrated Gastric Cancer Conference, Prof. Changqing Jing from Shandong Provincial Hospital summarized perioperative ICI trials in gastric cancer, discussing the status of ICIs in neoadjuvant and adjuvant settings and exploring the feasibility of future perioperative immunotherapy combinations.

The 2024 CACA Integrated Lung Cancer Conference, hosted by the Chinese Anti-Cancer Association and the Chinese Anti-Cancer Association’s Integrated Lung Cancer Committee (under preparation), was held in Zhuhai on October 25–26, 2024. With the theme “Uniting Efforts, Leading the Future,” the conference gathered leading domestic experts and scholars in the field of pulmonary tumors for in-depth and broad academic exchanges on hot and challenging topics related to lung cancer. During the conference, Oncology Frontier invited Dr. Gen Lin from the Cancer Center of Beijing Chest Hospital, Capital Medical University, for an exclusive interview. Professor Lin shared insights into the current clinical practice of immunotherapy for non-small cell lung cancer (NSCLC) and progress in strategies to address secondary resistance in immunotherapy.